At 24 weeks, mean relative liver-fat changes were 42.9%, 57.0%, 81.4%, and 82.4% with retatrutide 1 mg, 4 mg, 8 mg, and 12 mg, compared with +0.3% with placebo [6]
All three peptides show promising results in preclinical and early clinical studies, but further research is needed to confirm their long-term safety and efficacy
The largest difference was seen for the endpoint 1.0% HbA1c reduction and 3.0% weight loss, where for each JPY 1 spent on semaglutide, spending of JPY 2.45 was required with dulaglutide to achieve an equivalent clinical outcome
While Retatrutides nausea rates are lower than Semaglutides, someone who is already predisposed to GI sensitivity benefits from extra adaptation time
NF-B, nuclear factor kappa-B
Donors should have stable blood pressure and heart rate